DEF: Eli Lilly Reports Strong 2025, Proposes Governance Reforms

Eli Lilly reports exceptional 2025 financial and pipeline performance, alongside proposals to enhance corporate governance for shareholder approval.

Summary

• 2025 revenue reached $65.2 billion, marking a 45% increase.
• Reported EPS was $22.95, with non-GAAP EPS at $24.21, an 86% increase.
• Total Shareholder Return (TSR) for 2025 was 40%, consistently exceeding the S&P 500 and peer group TSR over 1, 3, and 5 years.
• Submitted orforglipron, an oral GLP-1 therapy, for obesity to regulatory authorities in the U.S. and Japan, and for obesity and type 2 diabetes in the EU.
• Received FDA approvals for an updated label for Kisunla in early symptomatic Alzheimer's disease and Omvoh's single-injection maintenance regimen in adults with ulcerative colitis.
• Presented positive Phase 3 results for Zepbound (SURMOUNT-5), showing an average weight loss of 20.2% versus 13.7% with Wegovy.
• Announced record manufacturing investments totaling over $15.7 billion across new facilities in the Netherlands ($3B), Puerto Rico ($1.2B), Virginia ($5B), and Texas ($6.5B).
• Acquired Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease.
• Generated or purchased approximately 80% of electricity from renewable sources in 2025.
• Proposing to eliminate the classified board structure and supermajority voting requirements from the articles of incorporation.
• Executive compensation programs received over 96% shareholder support in 2025, with the 2025 Bonus Plan payout at 218% and 2023 Shareholder Value Award (SVA) and Relative Value Award (RVA) payouts at 200% of target.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, reflecting exceptional financial performance, significant advancements in its drug pipeline, and substantial strategic investments in manufacturing and technology. The strong shareholder returns and high executive compensation payouts underscore a period of robust growth and successful execution, despite some persistent governance challenges.

Positives

• Achieved strong financial performance in 2025 with $65.2 billion in revenue and $24.21 non-GAAP EPS, representing significant year-over-year growth.
• Delivered a 40% Total Shareholder Return (TSR) in 2025, consistently outperforming the S&P 500 and its peer group over multiple periods.
• Made significant progress in the innovation pipeline, including regulatory submissions for orforglipron for obesity and type 2 diabetes.
• Secured key drug approvals for Kisunla (Alzheimer's) and Omvoh (ulcerative colitis), expanding treatment options for patients.
• Positive Phase 3 trial results for Zepbound (SURMOUNT-5) demonstrated superior weight loss (20.2%) compared to a leading competitor (Wegovy's 13.7%).
• Committed to substantial manufacturing investments exceeding $15.7 billion to enhance global supply chain and production capacity.
• Strategic acquisitions, such as Verve Therapeutics, expand the company's presence in promising areas like genetic medicines for cardiovascular disease.
• Advanced global health and sustainability initiatives, including sourcing approximately 80% of electricity from renewable sources in 2025.
• Proposed corporate governance reforms to eliminate the classified board structure and supermajority voting requirements, aiming to increase shareholder accountability.
• Executive compensation programs received overwhelming shareholder support (over 96%) and resulted in above-target payouts (218% for 2025 Bonus Plan, 200% for 2023 SVA and RVA), reflecting strong company performance.

Negatives

• The board opposes shareholder proposals to mandate an independent board chair and require an annual lobbying report, indicating potential areas of disagreement with certain investors.
• Previous attempts to eliminate the classified board structure and supermajority voting requirements (from 2010-2012 and 2018-2025) failed to achieve the required 80% shareholder vote, suggesting persistent challenges in enacting these governance changes.
• The company faces ongoing litigation and regulatory scrutiny, including a Texas lawsuit alleging bribing medical providers for GLP-1 medications and a Michigan investigation into insulin pricing practices, as highlighted by a shareholder proposal.

Risks

• Litigation and Regulatory Risks: The company is subject to ongoing legal proceedings and regulatory attention concerning product safety, commercial practices, alleged bribing of medical providers for GLP-1 medications, and insulin pricing practices.
• Forward-Looking Statements: Actual results could differ materially from forward-looking statements due to various risks detailed in the 2025 Annual Report on Form 10-K and other SEC filings.
• Cybersecurity Risks: The company continuously monitors cybersecurity risks, but these remain a significant threat requiring ongoing vigilance and enhancement of cyber resiliency.
• AI and Emerging Technologies: Risks are associated with the development and deployment of artificial intelligence and other emerging technologies, including through collaborations with third parties.
• Execution Risk in Manufacturing Expansion: While significant investments are planned, successfully expanding manufacturing capacity to meet rising global demand for innovative medicines at scale presents execution challenges.
• Shareholder Governance Dissent: The historical failure to achieve supermajority votes for proposed governance changes (classified board, supermajority voting) indicates a potential for continued shareholder activism or dissatisfaction with the pace of governance reform.

Future Outlook

The company aims to continue delivering innovative medicines, advancing promising research, and expanding capacity to meet global demand. It plans to further invest in breakthrough discoveries, including advanced drug development platforms and AI partnerships to accelerate treatment discovery. The company remains committed to its 30x30 goal of improving healthcare access for 30 million people in resource-limited settings annually by 2030 and advancing towards its 2030 climate goals, including renewable electricity sourcing. Governance improvements, such as eliminating the classified board and supermajority voting, are proposed to enhance shareholder accountability.

Management Comments

• 2025 was another year of significant progress for our company. We delivered innovative medicines to more patients, advanced promising research, and expanded our capacity to meet rising global demand.
• This initiative [agreement with U.S. government for obesity medicines] is designed to significantly reduce out-of-pocket costs for millions of Americans and reflects our commitment to affordability and patient access.
• We announced record manufacturing investments, with new facilities and global expansions expected to strengthen our supply chain and enable delivery of medicines at scale.
• Partnerships were forged to deploy AI to help decode biology, with the potential to accelerate the discovery of new treatments with unprecedented speed and precision.
• We remain committed to building on our legacy of innovation to improve human health for generations to come.
• Our purpose is to unite caring with discovery to create medicines that make life better for people around the world.
• We believe that high board effectiveness promotes the long-term interests of our shareholders, strengthens the accountability of the board of directors and management, and improves our standing as a trusted member of the communities we serve.
• Our compensation programs are designed to align executive pay with shareholder interests and link pay to performance through a blend of shortand long-term performance measures.

Industry Context

StockSavvy.ai notes that Eli Lilly's strong 2025 performance, particularly in GLP-1 therapies for obesity and diabetes, positions it as a leader in a highly competitive and rapidly expanding market segment. The substantial investments in manufacturing capacity reflect an industry-wide trend to scale production for blockbuster drugs and address global demand, especially for novel treatments. The strategic acquisitions and AI partnerships highlight the pharmaceutical industry's increasing reliance on advanced technology and external innovation to accelerate drug discovery and maintain a competitive edge. The company's focus on affordability and access, exemplified by the U.S. government agreement for obesity medicines, also reflects growing public and regulatory pressure on drug pricing and accessibility across the sector.

Comparison to Industry Standards

• Eli Lilly's 40% TSR in 2025 consistently exceeded the S&P 500 and its peer group TSR over 1, 3, and 5 years, indicating superior market performance compared to broader market and direct competitors.
• The SURMOUNT-5 trial results for Zepbound, demonstrating an average weight loss of 20.2% versus Wegovy's 13.7%, show a significant competitive advantage in the highly lucrative weight management market against Novo Nordisk's leading product.
• Lilly's clinical development speed and success rate are noted as performing 'above industry peers,' suggesting efficiency and effectiveness in its R&D pipeline compared to the broader pharmaceutical sector.
• The company's commitment to generating or purchasing approximately 80% of its electricity from renewable sources in 2025 positions it favorably against many industry peers in terms of environmental sustainability goals.
• Lilly's approach to board leadership, combining the chair and CEO roles with a strong lead independent director, aligns with all eight U.S.-incorporated companies in its pharma peer group, such as Johnson & Johnson and Merck, and 58% of S&P 500 companies as of April 30, 2025.
• The company's top-tier ranking (Tier 1) in the CPA-Zicklin Index for political spending transparency for two consecutive years indicates a leading position in corporate political disclosure compared to other S&P 500 companies.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed by the state of Texas in August 2025, alleging the company bribed and induced medical providers to prescribe its most profitable drugs, including GLP-1 medications.
• An ongoing investigation by the state of Michigan into the company's insulin pricing practices, with proceedings dating back to 2022.
• A lawsuit filed in July 2025 on behalf of the University of Pennsylvania and its health system, alleging 20 years of price fixing on diabetes drugs like insulin, naming Eli Lilly as one of three pharmaceutical company defendants.

Related Party Transactions

• In 2025, there were no related party transactions required to be reported pursuant to relevant SEC rules in this proxy statement. The board determined that transactions with entities affiliated with certain non-employee directors (e.g., medical/academic institutions, Archer-Daniels-Midland Company) fell below independence impairment thresholds and did not constitute related party transactions.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through strong financial performance, pipeline advancements, and strategic investments. Governance reforms (declassification, supermajority elimination) aim to increase accountability and influence. Executive compensation is strongly linked to shareholder returns.
• Patients: Benefit from innovative medicines, new drug approvals (e.g., Kisunla, Omvoh), and advancements in treatments for obesity, diabetes, cancer, and Alzheimer's. Initiatives to expand access and reduce out-of-pocket costs for obesity medicines (U.S. government agreement, LillyDirect) aim to improve affordability.
• Employees: Benefit from a comprehensive benefits program, competitive compensation, and a commitment to a healthy, vibrant, and inclusive work environment. The company's growth and manufacturing investments create job opportunities.
• Customers/Healthcare Providers: Access to new and improved medicines. Engagement with policymakers aims to support access to innovative medicines.
• Communities: Impacted by record manufacturing investments creating jobs and economic activity. Global health and sustainability initiatives aim to improve healthcare access in resource-limited settings and reduce environmental impact.
• Regulatory Authorities: Ongoing engagement and navigation of complex regulatory environments, including scrutiny over commercial practices and drug pricing.

Next Steps

• Shareholders to vote on director nominees, executive compensation, independent auditor ratification, and proposed amendments to articles of incorporation at the 2026 Annual Meeting on May 4, 2026.
• If approved, amendments to eliminate the classified board structure and supermajority voting provisions will become effective following the Annual Meeting upon required filings with the Secretary of State of Indiana.
• Directors elected after the 2026 Annual Meeting will serve one-year terms, with the classified board structure fully eliminated by the 2029 annual meeting.
• Continued engagement with shareholders on corporate governance and other issues.
• Ongoing efforts to progress the 30x30 goal for healthcare access and 2030 climate goals.
• Expected Medicare access for Zepbound by July 1, 2026.

Key Dates

Recommendation

The filing reveals exceptional 2025 financial performance, including a 45% revenue increase and 86% non-GAAP EPS growth, alongside a 40% TSR that significantly outpaced peers. Key drug approvals and positive Phase 3 trial results for high-demand therapies like Zepbound (outperforming Wegovy) underscore a robust and innovative pipeline. Substantial manufacturing investments exceeding $15.7 billion signal strong confidence in future growth and the ability to meet escalating demand. While governance reforms face historical hurdles, the underlying business momentum and market leadership in critical therapeutic areas make Eli Lilly a compelling "strong buy" for long-term investors.

Keywords

Pharmaceuticals, Biotech, Drug Development, Obesity, GLP-1, Alzheimer's, Oncology, Ulcerative Colitis, Corporate Governance, SEC Filing, Executive Compensation, Shareholder Return, R&D, Manufacturing, Sustainability, AI, Eli Lilly